CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 21 enrolled
Drug / intervention
SZKJT(San-Zhong-Kui-Jian-Tang)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05590650
NCT05590650Phase 1Completed
CompareCT.gov

A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients

China Medical University Hospital·interventional·Posted Oct 21, 2022·Updated Oct 26, 2022

In Brief

A Phase 1 clinical trial evaluating SZKJT(San-Zhong-Kui-Jian-Tang) for Head and Neck Neoplasm and Chemoradiotherapy. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to learn about the clinical efficacy of San-Zhong-Kui-Jian-Tang (SZKJT), a formula of Chinese medicine in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) treatments. The main questions it aims to answer are: * Can SZKJT improve the completion rate of CCRT? * Can SZKJT reduce the adverse effects of CCRT? * How SZKJT affect the quality of life in the patients receiving CCRT * How about the safety of using SZKJT in the patients receiving CCRT Participants will be asked to: * take SZKJT for 9 weeks during the whole CCRT course * take questionnaires of quality of life

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Neoplasm, Chemoradiotherapy
CountriesTaiwan
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 21, 2022
Enrollment StartJul 7, 2018
Primary CompletionJun 14, 2020
Study CompletionDec 25, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.7 years ago

Interventions

SZKJT(San-Zhong-Kui-Jian-Tang)drug

The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.